论文信息 - Predicting Relapse with Circulating Tumor DNA Analysis in Lung Cancer.

Predicting Relapse with Circulating Tumor DNA Analysis in Lung Cancer.

Advances in circulating tumor DNA (ctDNA) analysis are revealing new treatment strategies for patients with cancer. Detection of residual disease with ctDNA analysis predicts relapse with high accuracy after treatment for early-stage lung cancer. Cancer Discov; 7(12); 1368-70. ©2017 AACRSee related article by Chaudhuri et al., p. 1394.

N. Turner | I. Comino-Méndez

[1] Ash A. Alizadeh,et al. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. , 2017, Cancer Discovery.

[2] Ashwini Naik,et al. Phylogenetic ctDNA analysis depicts early stage lung cancer evolution , 2017, Nature.

[3] R. Strausberg,et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer , 2016, Science Translational Medicine.

[4] Jorge S. Reis-Filho,et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer , 2015, Science Translational Medicine.

[5] Mårten Fernö,et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease , 2015, EMBO molecular medicine.

[6] L. Diaz,et al. Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7] Ash A. Alizadeh,et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.

[8] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.

[9] B. Shapiro,et al. Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.